Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of a solid malignancy that is refractory to standard therapy or for which no standard therapy exists.~* Patients has a good performance status (ECOG 0 or 1)~Exclusion Criteria:~* Prior treatment with either pemetrexed or SU011248.~* Coughing up blood within 4 weeks before starting study treatment (small amounts okey).~* Hypertension that cannot be controlled by medications.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDD (Type: EXPERIMENTAL): None
- 2/1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).